However, this was not replicated in the latest published Cholesterol Lowering via Bempedoic Acid, and ACL-Inhibiting Regimen (CLEAR) Outcomes trial, which showed that treatment with bempedoic acid for patients without diabetes had no effect on the risk of new-onset T2DM or HbA1c levels [15], in line with our findings. This evidence concerns the gene ACLY and type 2 diabetes mellitus.